Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmac...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

vu_jade Jun. 16 at 10:23 PM

$CING if you had bought 1000 $RGC $5000 on January 2nd, and held you’d have $2,280,000 today … who says lightening can’t strike the same “spot” twice?

1 · Reply

Sam898989 Jun. 16 at 9:47 PM

$CING Summary of the latest transcript released by CING All clinical trials for CTX-1301 are completed and all data has been reported → Reduces development risk and increases visibility for next steps. Clinical trial data described as “unprecedented” in ADHD → Strong language suggests compelling efficacy/safety; potential for competitive edge. New Drug Application (NDA) is on track for late July–early August 2025 submission → Management is meeting stated milestones, shows execution discipline. Estimated FDA acceptance in Sept–Oct 2025 → Timeline is clear and imminent, reducing uncertainty. Targeting launch 12–14 months from now → Clear commercialization roadmap by mid–late 2026. CTX-1301 has fast onset (<30 min) and entire active-day coverage → Differentiated product features with high patient/provider value. Embedded 7-hour booster technology eliminates need for afternoon dose → Solves a long-standing ADHD treatment issue, particularly in teens and adults.

1 · Reply

IsaacSchorr Jun. 16 at 9:10 PM

$CING $RGC

0 · Reply

vu_jade Jun. 16 at 8:01 PM

$CING $RGC went from $5 to $2500 in 5 months.. why not Cingulate with the right news… If you own a stock up 19,000% maybe time to,buy another?

0 · Reply

vu_jade Jun. 16 at 7:45 PM

$CING based on RGC pump we could reach $8500 per share.. Giddy up

0 · Reply

vu_jade Jun. 16 at 7:35 PM

$CING buy low sell $RGC

0 · Reply

vu_jade Jun. 16 at 3:13 PM

$CING wants whatever the $RGC “traders” are smoking!

0 · Reply

vu_jade Jun. 16 at 2:47 PM

$CING calling all you 30c $RGC buyers here … ADHD worth $20 billion now? lol

0 · Reply

vu_jade Jun. 16 at 2:38 PM

$CING I just bought because of $RGC

0 · Reply

BiopharmaWatch_com Jun. 13 at 7:32 PM

🔍 NDA Filings: The Early Signal for Biotech Bulls 🔍 Curious why NDA filings matter? When a biotech files an NDA (New Drug Application), it’s their first shot at FDA approval showing confidence in their clinical data and moving one step closer to a commercial launch. These events often attract smart money early, before PDUFA dates and big headlines. Check out some of the recent NDA catalysts on the radar: $CING (CTx-1301, ADHD) PoA: 85% $NTRB (AVERSA Fentanyl patch) PoA: 60% $AQST (Anaphylm™ for allergic reactions) PoA: 85% $MDAI (DeepView® burn wound system) PoA: 85% $XRTX (XRx-026, gout) PoA: 40% 💡 Investor tip: NDA filing ≠ approval, but high Probability of Approval (PoA) and strong trial data can mean more eyes (and volume) before the FDA’s final say. For more NDA catalysts and PoA breakdowns, check biopharmawatch.com #Biotech #FDA #NDA #Catalysts #Stocks

1 · Reply

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 2 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 2 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 6 months ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 7 months ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 8 months ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 9 months ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 10 months ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 10 months ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 10 months ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 10 months ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 10 months ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 1 year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 1 year ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 1 year ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 1 year ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 1 year ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 1 year ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 1 year ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 1 year ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 1 year ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 1 year ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 1 year ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 1 year ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 1 year ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

May 12, 2023, 3:45 PM EDT - 2 years ago

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 10, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 3, 2023, 6:45 AM EDT - 2 years ago

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

Apr 4, 2023, 6:45 AM EDT - 2 years ago

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Mar 13, 2023, 6:45 AM EDT - 2 years ago

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Mar 10, 2023, 4:05 PM EST - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Feb 24, 2023, 7:04 AM EST - 2 years ago

Cingulate stock skyrockets after ADHD treatment shows positive trial results

Feb 23, 2023, 4:30 PM EST - 2 years ago

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

vu_jade Jun. 16 at 10:23 PM

$CING if you had bought 1000 $RGC $5000 on January 2nd, and held you’d have $2,280,000 today … who says lightening can’t strike the same “spot” twice?

1 · Reply

Sam898989 Jun. 16 at 9:47 PM

1 · Reply

IsaacSchorr Jun. 16 at 9:10 PM

$CING $RGC

0 · Reply

vu_jade Jun. 16 at 8:01 PM

$CING $RGC went from $5 to $2500 in 5 months.. why not Cingulate with the right news… If you own a stock up 19,000% maybe time to,buy another?

0 · Reply

vu_jade Jun. 16 at 7:45 PM

$CING based on RGC pump we could reach $8500 per share.. Giddy up

0 · Reply

vu_jade Jun. 16 at 7:35 PM

$CING buy low sell $RGC

0 · Reply

vu_jade Jun. 16 at 3:13 PM

$CING wants whatever the $RGC “traders” are smoking!

0 · Reply

vu_jade Jun. 16 at 2:47 PM

$CING calling all you 30c $RGC buyers here … ADHD worth $20 billion now? lol

0 · Reply

vu_jade Jun. 16 at 2:38 PM

$CING I just bought because of $RGC

0 · Reply

BiopharmaWatch_com Jun. 13 at 7:32 PM

1 · Reply

BullFunds Jun. 13 at 7:18 PM

$CING

0 · Reply

ZacksResearch Jun. 13 at 3:44 PM

🚀 $CING Gains 17% in Three Months: What is Driving the Stock? 📊 Phase 3 win in pediatric ADHD 🚨 Positive results from the CTx-1301-013 study confirmed that its 50mg ADHD treatment can be taken with or without food. This supports its aim to deliver a once-daily solution for ADHD management See what Wall Street expects next 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC

0 · Reply

BullFunds Jun. 13 at 3:32 PM

$CING market will crash and this will trash

0 · Reply

One2look Jun. 12 at 11:15 PM

$CING $DRUG $URGN 👇 I agree

0 · Reply

Trader1141 Jun. 12 at 10:31 PM

$URGN This will be like $DRUG or $CING

0 · Reply

denhopeforbest Jun. 12 at 5:12 PM

$CING honestly had gone up for no reason and then now down for a reason. big nothing.

0 · Reply

VicTruth17 Jun. 12 at 1:18 PM

$CING the JOHN FIFE EFFECT!

1 · Reply

Altomah Jun. 12 at 1:54 AM

$CING the market didn’t like the issuing of new shares of course the company value is the same and it will still be spread over more shares so in the end it will dilute our piece of the pie even if it’s staged and just to employees it’s still shares. I still like the idea that the FDA approval and next step look promising but i hate the manipulation of the value with our money

1 · Reply

HarryAye Jun. 11 at 3:38 PM

$CING At the Cingulate Inc. (the “Company”) 2025 Annual Meeting of Stockholders held on June 10, 2025 (the “Annual Meeting”), the Company’s stockholders approved Amendment No. 2 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the “Equity Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 800,000 shares (the “Amendment”). The board of directors of the Company had previously approved the Amendment, subject to stockholder approval, and the Amendment became effective upon such stockholder approval.

1 · Reply

trading_momentum Jun. 11 at 1:19 PM

$CING consolidating play that I’m watching for a breakout $FFAI squeeze play that looks to be back in play $UAVS flagging for potential next leg up

0 · Reply

PenkeTrading Jun. 11 at 1:19 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Cingulate Inc. Is that bullish or bearish? $CING #Cingulate #RsiOverbought #NASDAQ

1 · Reply

DonkeyClanbrands Jun. 11 at 11:17 AM

$CING can some one explain the difference in buying cing vs cingw I dont see cingw available on robinhood

1 · Reply

Market Cap	17.83M
Revenue (ttm)	0.00
Net Income (ttm)	-15.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	155,000
Avg Vol	165,842
Day's Range	N/A - N/A
Shares Out	4.25M
Stochastic %K	35%
Beta	-0.85
Analysts	Strong Sell
Price Target	$29.00